China has declared it wants to be the world’s leader in drug innovation, and its life science sector made remarkable progress toward becoming a global leader in 2016. With China’s thirteenth Five-Year Plan reinforcing the country’s focus on “biological technology”, the cross-border partnerships, M&A and VC investment in China’s life science industry is set to boom.
Research also shows that most of the deal making activity was in support of drug development and commercialization. In 2015, striking deals for pharma assets has become a primary means of leveraging the burgeoning China market, which is now the number two pharmaceutical market in the world.
“In the world of China life science, VC investment, M&A transactions, partnering activity, especially cross-border deals – all of these metrics were up substantially last year,” said Greg B. Scott, CEO and Founder of ChinaBio? LLC, a consulting and advisory firm based in Shanghai.
Rani Jarkas, Chairman of Cedrus Investments, an investment pioneer with years of experience in biotech and life science sector, said, “Innovation is complex and not all the necessary expertise, facilities and funding are available in each company’s region. China’s pursuit of life science development will drive Chinese healthcare SMEs to seek cross-border collaboration in the global scope.”
Rani Jarkas, the Chairman of Cedrus Investments.
Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas